427 related articles for article (PubMed ID: 23256518)
21. [Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
Schmidt S
Nervenarzt; 2010 Oct; 81(10):1231-41. PubMed ID: 20567960
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
23. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
[No Abstract] [Full Text] [Related]
24. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
[No Abstract] [Full Text] [Related]
25. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Comi G; Cook S; Giovannoni G; Rieckmann P; Sørensen PS; Vermersch P; Galazka A; Nolting A; Hicking C; Dangond F
Mult Scler Relat Disord; 2019 Apr; 29():168-174. PubMed ID: 30885375
[TBL] [Abstract][Full Text] [Related]
26. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
Leist TP; Comi G; Cree BA; Coyle PK; Freedman MS; Hartung HP; Vermersch P; Casset-Semanaz F; Scaramozza M;
Lancet Neurol; 2014 Mar; 13(3):257-67. PubMed ID: 24502830
[TBL] [Abstract][Full Text] [Related]
27. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
28. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
[TBL] [Abstract][Full Text] [Related]
29. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
Leist TP; Vermersch P
Curr Med Res Opin; 2007 Nov; 23(11):2667-76. PubMed ID: 17880754
[TBL] [Abstract][Full Text] [Related]
30. Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Meuth SG; Bayas A; Kallmann B; Kleinschnitz C; Linker R; Rieckmann P; Mäurer M
Expert Opin Pharmacother; 2020 Nov; 21(16):1965-1969. PubMed ID: 32658554
[TBL] [Abstract][Full Text] [Related]
31. Cladribine tablets: in relapsing-remitting multiple sclerosis.
Muir VJ; Plosker GL
CNS Drugs; 2011 Mar; 25(3):239-49. PubMed ID: 21323395
[TBL] [Abstract][Full Text] [Related]
32. Oral cladribine and fingolimod for relapsing multiple sclerosis.
Li H; Zhang X
N Engl J Med; 2010 May; 362(18):1738-9; author reply 1739-40. PubMed ID: 20449878
[No Abstract] [Full Text] [Related]
33. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods].
Meuth SG; Ruck T; Aktas O; Hartung HP
Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912
[TBL] [Abstract][Full Text] [Related]
34. Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Stępień A; Pogoda-Wesołowska A; Tokarz-Kupczyk E; Słowik A; Puz P; Adamczyk-Sowa M; Kurkowska-Jastrzębska I; Kułakowska A; Chorąży M; Piasecka-Stryczyńska K; Jamróz-Wiśniewska A; Bartosik-Psujek H; Rejdak K
Neurol Neurochir Pol; 2023; 57(4):371-378. PubMed ID: 37490356
[TBL] [Abstract][Full Text] [Related]
35. Cladribine Tablets: A Review in Relapsing MS.
Deeks ED
CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527
[TBL] [Abstract][Full Text] [Related]
36. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
37. Cladribine: an investigational immunomodulatory agent for multiple sclerosis.
Brousil JA; Roberts RJ; Schlein AL
Ann Pharmacother; 2006 Oct; 40(10):1814-21. PubMed ID: 16985095
[TBL] [Abstract][Full Text] [Related]
38. Oral treatment for multiple sclerosis.
Killestein J; Rudick RA; Polman CH
Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
[TBL] [Abstract][Full Text] [Related]
39. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
Mankinen P; Lundström T; Soini E; Sumelahti ML; Ruutiainen J; Niskala U; Järvinen E
Adv Ther; 2020 Feb; 37(2):800-818. PubMed ID: 31873868
[TBL] [Abstract][Full Text] [Related]
40. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
De Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist T; Coyle PK; Dangond F; Keller B; Alexandri N; Galazka A
Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]